HCRTR2
ENSG00000137252
Target class
GPCR
Chromosome
6
Approved drugs
4
Clinical candidates (approved and in development)
9
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- Yes
- Target name
- HCRTR2
- Gene name
- Hypocretin receptor 2
- Gene symbol
- HCRTR2
- Protein name
- Orexin receptor type 2 (Ox-2-R) (Ox2-R) (Ox2R) (Hypocretin receptor type 2)
- OX2R
- OXR2
- ORXR2
- Gene biotype
- Protein coding
- Gene family
- Hypocretin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 0
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 0.71
- Tissue specificity (Gini)
- 0.774
- Tissue specificity (tau)
- 0.918
- KEGG gene identifiers
- hsa:3062
- Protein interaction confidence
- 0.890143
- Protein interaction partners
- 7
- R-HSA-389397
- R-HSA-416476
- End position
- 55282617
- Start position
- 55106460
- Chromosome
- 6
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein .
- Nucleoplasm
- Plasma membrane
- PubMed 26950369
- PubMed 9491897
- PubMed 25533960
- Tissue specificity (tau)
- 0.918416
- Expression inequality (Gini)
- 0.773663
Expression in transcripts per million
- Brain - Hypothalamus
- 0.71
- Testis
- 0.5
- Brain - Frontal Cortex (BA9)
- 0.38
- Brain - Cortex
- 0.31
- Brain - Anterior cingulate cortex (BA24)
- 0.27
Expression in transcripts per million
- Brain - Hypothalamus0.71
- Testis0.5
- Brain - Frontal Cortex (BA9)0.38
- Brain - Cortex0.31
- Brain - Anterior cingulate cortex (BA24)0.27
- Brain - Nucleus accumbens (basal ganglia)0.22
- Brain - Substantia nigra0.2
- Brain - Amygdala0.18
- Ovary0.12
- Heart - Atrial Appendage0.11
- Lung0.08
- Kidney - Medulla0.08
- Brain - Caudate (basal ganglia)0.08
- Brain - Putamen (basal ganglia)0.06
- Brain - Cerebellum0.05
- Brain - Cerebellar Hemisphere0.05
- Artery - Coronary0.05
- Pituitary0.05
- Brain - Hippocampus0.05
- Cervix - Endocervix0.04
- Brain - Spinal cord (cervical c-1)0.04
- Adipose - Visceral (Omentum)0.03
- Adipose - Subcutaneous0.03
- Nerve - Tibial0.03
- Kidney - Cortex0.03
And 29 more, listed on the interactive page.
- GO:0007218
- GO:0007268
- GO:0007631
- GO:0051480
Cellular components
- GO:0005886
- GO:0005515
- GO:0008188
- GO:0016499
Related records
Trials (236)
- 15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.
- 2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects
- A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
- A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion
- A Clinical Pharmacology Study of TS-142 in Patients with Obstructive Sleep Apnea Hypopnea.
- A Clinical Study to Assess Next-day Driving Performance Following Administration of ACT-541468 in Middle-aged and Elderly Subjects
- A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population
- A Clinical Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 in Healthy Male Subjects
- A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam
- A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study
- A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922
- A Dual Orexin Receptor Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insomnia.
- A Food Effect Study of TS-142 in Healthy Subjects
- A Long Term Safety Study of Suvorexant in Participants With Primary Insomnia (MK-4305-009 AM3)
- A Multicenter Observational Study of Lemborexant on Insomnia Patients With Psychiatric Disorders
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
- A Pharmacokinetic Study of TS-142 in Patients with Hepatic Impairment
- A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants
- A Phase I Study of TS-142 in Healthy Participants (Repeated Doses)
- A Phase I Study of TS-142 in Healthy Participants (Single Doses)
Drugs (9)
- Almorexant Orexin receptor antagonist
- Daridorexant Orexin receptor antagonist
- Daridorexant hydrochloride Orexin receptor 2 antagonist
- Filorexant Orexin receptor antagonist
- Lemborexant Orexin receptor 2 antagonist
- Orn-0829 hydrate Orexin receptor antagonist
- SB-649868 Orexin receptor 2 antagonist
- Seltorexant Orexin receptor 2 antagonist
- Suvorexant Orexin receptor antagonist